- CytoSorbents Reports First Quarter 2024 Results
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
- CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
More ▼
Key statistics
As of last trade Cytosorbents Corp (CTSO:NAQ) traded at 0.8092, 3.48% above its 52-week low of 0.782, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.83 |
---|---|
High | 0.85 |
Low | 0.80 |
Bid | 0.80 |
Offer | 0.8092 |
Previous close | 0.81 |
Average volume | 107.72k |
---|---|
Shares outstanding | 54.31m |
Free float | 52.57m |
P/E (TTM) | -- |
Market cap | 43.99m USD |
EPS (TTM) | -0.6375 USD |
Data delayed at least 15 minutes, as of May 10 2024 15:36 BST.
More ▼